Invivyd shares are trading higher after the company announced 180-day exploratory clinical efficacy data from the CANOPY Phase 3 trial of Pemivibart, showing an 84% relative risk reduction in symptomatic COVID-19 compared to placebo.
Portfolio Pulse from Benzinga Newsdesk
Invivyd's shares rose following the announcement of positive 180-day exploratory clinical efficacy data from the CANOPY Phase 3 trial of Pemivibart, which showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo.
August 27, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd's stock is trading higher due to positive results from the CANOPY Phase 3 trial of Pemivibart, demonstrating significant efficacy in reducing symptomatic COVID-19.
The announcement of an 84% relative risk reduction in symptomatic COVID-19 from the CANOPY Phase 3 trial is a significant positive development for Invivyd, likely boosting investor confidence and driving the stock price higher.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100